Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis.
Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis.
复制标题
DOI:
10.3389/fphar.2018.00144
复制
发表时间:
2018
影响因子:
5.6
通讯作者:
Jin D
中科院分区:
文献类型:
--
作者:
Takai S;Jin D
Non-alcoholic steatohepatitis (NASH) is characterized by inflammation and fibrosis, in addition to steatosis, of the liver, but no therapeutic agents have yet been established. The mast cell protease chymase can generate angiotensin II, matrix metalloproteinase-9 and transforming growth factor-β, all of which are associated with liver inflammation or fibrosis. In animal models of NASH, augmented chymase has been observed in the liver. In histological analysis, chymase inhibitor prevented hepatic steatosis, inflammation, and fibrosis. Chymase inhibitor also attenuated the augmentation of angiotensin II, matrix metalloproteinase-9, and transforming growth factor-β observed in the liver of NASH. Oxidative stress, inflammatory markers, and collagen were attenuated by chymase inhibition. Moreover, chymase inhibitor showed a mitigating effect on established NASH, and survival rates were significantly increased by treatment with chymase inhibitor. In this review, we propose that chymase inhibitor has potential as a novel therapy for NASH.
登录
查看更多内容
DOI:
10.1152/ajpgi.00162.2009
发表时间:
2009-10-01
影响因子:
4.5
作者:
Colmenero, Jordi;Bataller, Ramon;Gines, Pere
通讯作者:
Gines, Pere
影响因子:
15.9
作者:
KAGAMI, S;BORDER, WA;NOBLE, NA
通讯作者:
NOBLE, NA
DOI:
10.1073/pnas.96.22.12719
发表时间:
1999-10-26
影响因子:
11.1
作者:
George, J;Roulot, D;Bissell, DM
通讯作者:
Bissell, DM
影响因子:
2.4
作者:
Arias M;Sauer-Lehnen S;Treptau J;Janoschek N;Theuerkauf I;Buettner R;Gressner AM;Weiskirchen R
通讯作者:
Weiskirchen R
影响因子:
4.2
作者:
Komeda, Koji;Takai, Shinji;Miyazaki, Mizuo
通讯作者:
Miyazaki, Mizuo